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Engaging the antibody-dependent cell-mediated cytotoxicity (ADCC) for killing of 
virus-infected cells and secretion of antiviral cytokines and chemokines was incorporated 
as one of the important features in the design of universal influenza vaccines. However, 
investigation of the ADCC epitopes on the highly immunogenic influenza hemagglutinin 
(HA) head region has been rarely reported. In this study, we determined the ADCC and 
antiviral activities of two putative ADCC epitopes, designated E1 and E2, on the HA 
head of a pandemic H1N1 influenza virus in vitro and in a lethal mouse model. Our data 
demonstrated that sera from the E1-vaccinated mice could induce high ADCC activities. 
Importantly, the induction of ADCC response modestly decreased viral load in the lungs 
of H1N1-infected mice. However, the elevated ADCC significantly increased mouse 
alveolar damage and mortality than that of the PBS-vaccinated group (P < 0.0001). The 
phenotype was potentially due to an exaggerated inflammatory cell infiltration triggered 
by ADCC, as an upregulated release of cytotoxic granules (perforin) was observed in 
the lung tissue of E1-vaccinated mice after H1N1 influenza virus challenge. Overall, our 
data suggested that ADCC elicited by certain domains of HA head region might have 
a detrimental rather than protective effect during influenza virus infection. Thus, future 
design of universal influenza vaccine shall strike a balance between the induction of 
protective immunity and potential side effects of ADCC.
Keywords: antibody-dependent cell-mediated cytotoxicity, h1n1 influenza virus, hemagglutinin, lung damage, 
mice
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inTrODUcTiOn
Influenza viruses, as one of the major zoonotic pathogens, have 
continuously caused global health concerns due to their high 
propensity for unpredictable genetic mutation in major surface 
antigens, hemagglutinin (HA), and neuramindase. Antivirals and 
vaccines are vital in combating the threat of influenza epidemics 
and pandemics. However, the increasing usage of licensed antivi-
rals has resulted in the global emergence of amantadine- and/or 
oseltamivir-resistant strains of influenza virus. Typical examples 
include the worldwide spread of adamantine resistant A(H3N2) 
viruses since 2003, oseltamivir-resistant seasonal A(H1N1) 
viruses since 2007, adamantane-resistant pandemic A(H1N1) 
viruses in 2009, and peramivir-resistant A(H7N9) viruses in 
2013 (1). On the other hand, seasonal influenza vaccines have 
to be updated annually due to the continuous antigenic drift and 
shift (2). Otherwise, the mismatch between vaccinated formula-
tions and that of natural selection would considerably limit the 
effectiveness of influenza vaccines.
Neutralizing antibodies have traditionally been thought 
to provide protection against influenza viruses. Nevertheless, 
the effectiveness induced by such vaccines is limited by the 
emergence of mutant viruses that are resistant to antibody-
mediated neutralization (3). In this regard, the quest for 
universal influenza vaccines has fueled the interest in broadly 
reactive antibodies in addition to direct virus neutralizations. 
Antibody-dependent cell-mediated cytotoxicity (ADCC) uses 
effector arms of both innate and adaptive immune responses to 
eliminate target cells. Natural killer (NK) cells, upon triggered 
by specific ADCC antibodies, mediate the clearance of virus-
infected cells (4). The NK  cell CD16 receptor recognizes the 
Fc portion of IgG1 antibodies that in turn bind to antigens on 
virus-infected cells (5). This interaction induces degranulation 
of NK cells to release perforin/granzymes as well as secretion 
of antiviral cytokines such as interferon-γ (IFN-γ) and tumor 
necrosis factor-α (TNF-α) (5).
Since ADCC could invoke protective immune response 
against infections from a broad array of viruses, the ADCC anti-
body response was incorporated as one of the most important 
features of potential universal vaccine candidates by the World 
Health Organization. Notably, multiple components of influenza 
viruses are known to induce ADCC, including the viral surface 
proteins such as HA (6) and M2 ectodomain (7, 8), as well as 
the internal proteins including NP and M1 (9). The glycoprotein 
HA consists of two functional domains, the immunodominant 
globular head domain and the more conserved stalk domain (10). 
Conventionally, neutralizing antibody response to influenza virus 
is dominated by antibodies that target the head region, which 
block the virus receptor-binding site. Compared with the bulky 
globular HA head, the HA stem region is far less immunogenic, 
and antibodies directed to this domain occur at a relatively low 
frequency. However, a rare class of neutralizing antibodies that 
target a conserved site in the HA stem was reported recently, 
which might shed new light for the development of universal 
influenza vaccines (6).
We have previously identified two putative ADCC epitopes 
that mapped to the HA head of a pandemic H1N1 influenza virus 
(11). Both epitopes, designated E1 and E2, revealed by epitope 
mapping of convalescent-phase plasma IgG antibodies from 
six H1N1-infected human subjects, are dominant and highly 
conserved (11). In this study, we further dissected the function 
of the two ADCC epitopes in vitro and in a lethal mouse model. 
Surprisingly, our results demonstrated that the ADCC response 
elicited by the E1 epitope triggered a detrimental rather than 
protective effect against influenza virus infection. While the anti-
viral efficacy provided by the stalk-specific ADCC antibodies has 
been confirmed (12), our data raised concerns on the side effect 
of certain HA head epitopes in devising a universal influenza 
vaccine. In this regard, our study suggested that a delicate bal-
ance between protective immunity and over induction of ADCC 
should be maintained, which should be an important considera-
tion in evaluating vaccine safety.
MaTerials anD MeThODs
cells and Viruses
The LA4 cell line, which was derived from mouse lung adenoma, 
was maintained in DMEM/F-12 medium (Gibco) supplemented 
with 20% heat-inactivated fetal bovine serum (FBS), 50  U/ml 
penicillin, and 50  μg/ml streptomycin (P/S). Peripheral blood 
mononuclear cells (PBMCs) were prepared by Ficoll-Paque 
separation (13) of heparinized whole blood obtained from 
healthy BALB/c mice (6–8  weeks old). To prepare the ADCC 
target cells, LA4 cells were transfected with an HA expression 
plasmid that based on the cDNA fragment of influenza virus 
strain A/Hong Kong/415742/2009(H1N1)pdm09. Specifically, 
the full-length HA fragment was cloned into a mammalian 
expression vector pEAK10 plasmid containing a mouse IgG1 Fc 
gene (CH2 + CH3) (14). The pandemic H1N1 influenza virus 
strain A/Hong Kong/415742/2009(H1N1)pdm09 was used 
for in  vitro virus infection; while its mouse-adapted version, 
A/Hong Kong/415742Md/2009 (H1N1)pdm09 was propagated 
in embryonated hens’ eggs and utilized for in vivo experiment 
(15). The viruses were stored in −80°C in aliquot and titrated 
by standard plaque assay. All experiments with live viruses were 
conducted using biosafety level 2 facilities as described previ-
ously (16).
Mouse study
BALB/c female mice, 6–8 weeks old, were kept in biosafety level 
2 housing and given access to standard pellet feed and water 
ad  libitum. All experimental protocols followed the standard 
operating procedures of the biosafety level 2 animal facilities and 
were approved by the Animal Ethics Committee in the University 
of Hong Kong (17).
Vaccination
Vaccinations were carried out to immunize the mice with E1 or 
E2 or HA epitopes by DNA priming and protein boost. PBS was 
used as a negative control. The specified vaccination scheme was 
listed in Table 1. To prepare the DNA plasmids, either of the E1 
or E2 fragment (11) was cloned into the mammalian expression 
vector pEAK10 as described for the HA plasmid construction. 
The resultant plasmid DNA (100 μg per mice) was used for DNA 
TaBle 1 | Mouse vaccinations scheme.
inoculation and bleed Day PBs group (n = 15) e1 group (n = 15) e2 group (n = 15) hemagglutinin (ha) group (n = 15)
Bleed 0 0 6- to 8-week female mice
Primary inoculate (DNA) 1 PBS (100 μl) E1 plasmid (100 μg/100 μl) E2 plasmid (100 μg/100 μl) HA plasmid (100 μg/100 μl)
Bleed 1 28
Boost 1 (DNA) 29 PBS (100 μl) E1 plasmid (100 μg/100 μl) E2 plasmid (100 μg/100 μl) HA plasmid (100 μg/100 μl)
Boost 2 (protein)a 43 PBS (100 μl) E1 protein (25 μg/100 μl) E2 protein (25 μg/100 μl) HA protein (25 μg/100 μl)
Boost 3 (protein)a 57 PBS (100 μl) E1 protein (25 μg/100 μl) E2 protein (25 μg/100 μl) HA protein (25 μg/100 μl)
Bleed 2 68
Virus challenge 69 (1,000 FPU/mouse for all groups, record the mouse body weight, and survival every day, until day 83)
aSigma adjuvant system was added as adjuvant.
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priming of the mice by electroporation. To prepare protein for 
vaccination, recombinant HA, E1, and E2 fusion proteins were 
expressed in FreeStyle 293FT™ transient expression system 
(Invitrogen) and purified by protein A affinity (GE Healthcare). 
Subsequently, proteins were dialyzed and concentrated with 
Vivaspin 20 centrifugal concentrator (GE Healthcare), followed 
by protein boosting through intramuscular route. Each mouse 
received 25  μg protein at each protein boosting. Sera were 
obtained at day 68 postimmununization before virus challenge. 
Antibody titers raised against E1, E2, and HA in mouse sera were 
evaluated by ELISA as previously described with some modifica-
tions (18). Mouse sera collected from the PBS-treated group were 
taken as a background control.
Virus challenge study
Immunized mice (15 mice/group) were inoculated with five 50% 
lethal dose (LD50) of mouse-adapted pandemic H1N1 influenza 
virus by intranasal route, i.e., 1,000 PFU/mouse. Animal survival 
and body weight were monitored daily for 14 days after virus chal-
lenge. A body weight loss of 30% was set as the humane endpoint. 
Three mice per group were randomly selected and euthanized 
on day 3 and 5 post-challenge, respectively. Mouse lungs were 
collected from the euthanized mice. Half of the lung tissues were 
harvested for virus titration by RT-qPCR methods (19), while 
the other half were immediately fixed in 10% of PBS buffered 
formaldehyde for histopathological analyses as described previ-
ously (20).
histopathological assessment
Slides were examined in a blinded manner and scored with 
a semiquantitative system according to the relative degree of 
inflammation and tissue damage (21–24). Inflammation was 
scored as follows: 0, no inflammation; 1, perivascular cuff of 
inflammatory cells; 2, mild inflammation (extending through-
out 25% of the lung); 3, moderate inflammation (25–50% of 
the lung); 4, severe inflammation involving over one half of 
the lung.
aDcc assay
Antibody-dependent cell-mediated cytotoxicity activity, reflected 
by the rate of cell death, was measured by a flow cytometry-based 
assay that described previously with some modifications (11). 
Generally, the PKH-67 dye (Sigma) was utilized to label the target 
cells, i.e., HA-transfected LA-4 cells; while 7-Aminoactinomycin 
D (7-AAD; Invitrogen) was used to stain the dead cells that medi-
ated by ADCC activity. Experimentally, PKH-67-labeled target 
cells and unlabeled effector cells (i.e., PBMCs) were prepared in 
RPMI 1640 medium (Gibco) containing 10% FBS and 1% P/S with 
a cell density of 106 and 108 cells/ml, respectively. Subsequently, 
50 μl of target cells were dispensed into a round-bottom 96-well 
plate, followed by addition of 1 μl of mouse serum. Mouse serum 
concentration in each group was normalized before addition 
according to their titers determined by ELISA. One hour after 
incubation, 50 μl of effector cells were added to incubate with the 
target cells. Three hours later, another 1 μl of 7-AAD was added 
to each well before performing the flow cytometry. Cell death 
was determined with a FACSAria III flow cytometer using the 
BD FACS software (BD Biosciences). Percent cell death was cal-
culated by software analysis of four identifiable cell populations: 
live effector cells (no dye), dead effector cells (7-AAD positive), 
live target cells (PKH-67 positive), and dead target cells (PKH-67 
and 7-AAD double positive). Assay controls used to define cell 
populations included target cells alone (background cell death) 
and target cells with 1 μl Triton X-100 added (maximum cell 
death). Percent ADCC was calculated as [(percent experimental 
lysis − percent spontaneous lysis)/(percent maximum lysis − per-
cent spontaneous lysis)] × 100%, in which percent spontaneous 
lysis refers to the percent lysis of infected cells with effectors but 
in the absence of serum, while percent maximum lysis refers to 
the percent lysis of infected cells with effectors in the presence of 
1% Triton X-100. Experiments were performed in triplicate and 
repeated twice for confirmation.
confocal imaging
Immunostaining was performed as previously described to 
visualize perforin expression in mouse lung tissues (25). 
Rat anti-mouse perforin (abcam Ab16074) and goat anti-rat 
Alexa 594 were used as primary and secondary antibodies, 
respectively. Images were acquired with a Carl Zeiss LSM 780 
system.
Quantitative real-time rT-Pcr
RNA extraction, reverse transcription, and qPCR were performed 
as previously described (26, 27). In brief, total RNA was extracted 
FigUre 1 | Detection of binding activities in mouse serum samples. 
ELISA was used to measure antibody titers in serum samples collected from 
the mice vaccinated with E1 (E1-serum), E2 (E2-serum), HA (HA-serum), or 
PBS (PBS-serum) on day 68. Binding was tested against either the antigen 
E1-Fc (a) or E2-Fc (B), respectively. Binding intensities were measured at an 
absorbance of 450 nm. The experiments were conducted in triplicate. Data 
shown represents the mean values ± SD (n = 6).
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from mouse lung with RNeasy Mini Kit (Qiagen) and reverse 
transcribed with Transcriptor First Strand cDNA Synthesis Kit 
(Roche). Real time PCR was performed using LightCycler® 96 
(Roche) machine according to the manufacturer’s instructions. 
Relative gene expression was normalized to the corresponding 
β-actin values. The sequences of the primers for RT-qPCR are 
listed in Table S1 in Supplementary Material.
statistical analysis
Statistical comparison was performed by Student’s t-test using 
GraphPad Prism 6. Differences were considered statistically 
significant when P < 0.05.
resUlTs
aDcc responses are enhanced by the 
sera of e1-Vaccinated Mice
In our previous study, we mapped two putative ADCC epitopes, 
E1 and E2, on the HA head region. By depleting E1 and/or E2 
from clinical plasma IgG antibodies, the ADCC activity dropped 
significantly, which suggested that the two epitopes played 
potential roles in eliciting ADCC (11). In this study, we sought 
to confirm the function of these putative epitopes in the induc-
tion of ADCC activity using a mouse model. Immunization of 
mice gave raise to IgG titers against the E1, E2, or HA protein, 
as quantified by ELISA (Figure 1). A prime/boost immunization 
strategy was adopted, and mice that immunized with PBS or HA 
were included as a negative or a positive control, respectively 
(Table 1). Our results indicated that serum samples from mice 
vaccinated with E1 (Figure 1A) or E2 (Figure 1B) both exhibited 
strong dilution-dependent antibody responses, reaching a titer of 
more than 1:5000. Additionally, using HA as the coating antigen 
for ELISA, we demonstrated that E1 and E2 sera could bind full-
length HA at a comparable efficiency (Figure S1 in Supplementary 
Material). Taken together, our data suggested that the vaccination 
was successful and the resultant serum samples could be utilized 
for further investigations.
Next, ADCC activities in serum samples from E1-, E2-, or 
HA-immunized mice were evaluated by flow cytometry-based 
ADCC assays. To this end, the HA-transfected LA4 cells were 
labeled with the cell-membrane marker PKH67 and utilized as 
target cells for ADCC-specific antibody binding. Subsequently, 
the vaccinated mouse serum was added to bridge the interac-
tion between target cells and PBMC effector cells (Figure  2). 
The presence of ADCC-mediating antibody was determined 
by analyzing the cytotoxicity rate within the cell mixture that 
contained the target cells, serum, and effector cells, in which 
the dead target cell population was revealed by the cell death 
marker, 7AAD (Figure  3). As shown in Figures  3A–G, sera 
from the E1-vaccinated mice consistently triggered the highest 
7AAD  +  rate among all evaluated groups, suggesting that a 
higher percentage of cell lysis was induced in the E1 group in 
comparison to the other groups. The percentage of cytotoxicity 
was normalized using the formula reported by Srivastava et al., 
with spontaneous and maximum cell cytotoxicity rate taken into 
consideration (11). Quantitatively, sera from the E1-vaccinated 
mice elicited a significantly increased (P < 0.05) ADCC activity 
in comparison with the PBS-vaccinated group (Figure 3H). Of 
note, though sera from the E2-Vaccinated mice triggered a subtle 
increase in ADCC activity, the difference was not statistically 
significant (Figure  3H). Intriguingly, albeit HA contained the 
E1 epitope, sera from the HA-vaccinated group did not induce a 
significantly elevated cytotoxicity response in comparison to that 
of the PBS control group (Figure 3H).
e1-Vaccinated Mice are adversely 
affected by aDcc
Since E1 was capable of inducing ADCC activities, we hypoth-
esized that E1-vaccinated mice could potentially be protected 
by the elicited ADCC activity after influenza virus challenge. 
To this end, we inoculated the vaccinated mice with pandemic 
H1N1 influenza virus in a lethal mouse model (Figure  4A). 
As shown in Figure 4B, mice in the HA-vaccinated group, as a 
positive control, demonstrated a substantial reduction of viral 
load on both day 3 and day 5 post-inoculation in comparison 
to the PBS-vaccinated group. Importantly, we detected an 
approximately one log decrease of viral load in the mouse 
lungs of the E1-vaccinated group in comparison to that of the 
PBS-vaccinated group on day 5 post-inoculation, while no sig-
nificant difference could be observed between the two groups 
on day 3 post-virus challenge (Figure  4B). In addition, the 
viral load in the lungs of the E1-vaccinated mice was notably 
lower on day 5 when compared with that of day 3, suggesting 
that the ADCC effect was triggered between day 3 and 5 post-
inoculation (Figure 4B).
FigUre 2 | schematic diagram of the antibody-dependent cell-mediated cytotoxicity (aDcc) assay. ADCC activity was determined by a flow cytometry-
based assay using two fluorescent dyes. PKH-67, a membrane-labeling dye, was used to specifically identify the HA-transfected target cells. 7AAD was excluded 
by viable cells but could penetrate the cell membrane of dead or dying cells and intercalate into double-stranded DNA. Briefly, 50 μl of PKH-67-labeled target cells 
(106 cells/ml) was dispensed into a round-bottom 96-well plate, followed by addition of E1/E2/HA/PBS sera and effector/PBMC cells. Following a 3-h incubation, 
7-AAD was added. Cell death was determined on a FACSAria III flow cytometer using BD FACS Diva software (BD Biosciences). Percent cell death was analyzed by 
the Flowjo software.
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In parallel, we measured the survival rate and body weight 
changes of the mice. As shown in Figure 4C, all mice from the 
HA-vaccinated group survived the course of infection while all 
mice received PBS-treatment died, indicating that the virus chal-
lenge was successful. Unexpectedly, our results demonstrated 
that the mice in the E1-vaccinated group succumbed to influenza 
virus infection at a significantly earlier time (P < 0.0001) post-
inoculation when compared with that of the PBS-vaccinated con-
trol group (Figure 4C). In line with the survival rate, mice from 
the E1-vaccinated group suffered from an apparently accelerated 
weight lost starting on day 3 post-inoculation in comparison to 
mice from the PBS- and E2-vaccinated groups, although the dif-
ference did not reach statistical significance (Figure 4D).
Next, we carried out histopathological examinations on the 
lung sections of the virus-infected mice. Using uninfected mouse 
lung tissues as a control (Figures 5I,J), our observation showed 
that on both day 3 and day 5, mice from the HA-vaccinated group 
(Figures  5G,H) exhibited ameliorated alveolar morphology 
changes when compared with those from the E1 (Figures 5C,D), 
E2 (Figures 5E,F), and PBS (Figures 5A,B) groups. Importantly, 
the lung pathological scores of mice from the HA-vaccinated 
group on both day 3 and day 5 were significantly lower than those 
of the PBS-treated mice (Figures  5K,L); while mice from the 
E1-vaccinated group suffered from a significantly more dramatic 
interstitial inflammatory infiltration than that of the PBS-treated 
mice on day 5 (Figure 5L). This result indicated that the detri-
mental lung damage of E1-vaccinated mice, possibly triggered by 
ADCC, might account for the reduced viral load in lungs as well 
as the earlier drop in survival.
To address whether the severe lung damage in the 
E1-vaccinated group could be attributed to the ADCC effect, we 
performed immunofluorescence staining to visualize the expres-
sion level of perforin among different mouse groups. Perforin is 
released by activated NK cells and is known as a marker of ADCC 
activation (28). As quantitated in Figure 6M, the E1-vaccinated 
mice (Figures 6D–F) demonstrated the highest perforin expres-
sion level in the lung sections amongst the other three groups on 
day 5 post infection (Figures 6A–C,G–L). However, the mRNA 
expression level of perforin was not significantly different across 
all evaluated groups (Figure 6N).
Binding of Fc receptor (FcR) on effector cells triggers the 
secretion of cytotoxic granules as well as antiviral cytokines 
and chemokines, such as IFN-γ and TNF-α (4). To investigate 
if elevated expression of proinflammatory cytokines might con-
tribute to the lung damage, we measured the mRNA expression 
level of representative cytokines including TNF-α (Figure 7A), 
IL-1β (Figure 7B), and IFN-γ (Figure 7C) in the mouse lungs 
samples. Our results showed that the gene expression of all three 
proinflammatory cytokines were significantly enhanced in the 
E1-vaccinated group when compared with those of the PBS-
treated group (Figure 7), which were in line with the perforin 
protein expression pattern in Figure 6. Together, our data sug-
gested that the E1 epitope from the HA head domain mediated 
unfavorable ADCC that resulted in a more severe lung damage 
and exacerbated mouse mortality despite a successful control of 
the H1N1 influenza viral load.
DiscUssiOn
Antibody-dependent cell-mediated cytotoxicity, as a bridge of the 
innate and adaptive immunity, plays important roles in humoral 
and cellular immune response (4, 9). Since ADCC antibodies are 
FigUre 3 | antibody-dependent cell-mediated cytotoxicity (aDcc) 
responses are enhanced by the sera of e1-vaccinated mice. ADCC 
activities in serum samples collected on day 68 were tested by flow 
cytometry-based assays. (a) Gating of LA4 cells. (B) Gating of PKH67 
positive cells. The 7AAD positive cell population for the no serum group (c), 
PBS-vaccinated group (D), E1-vaccinated group (e), E2-vaccinated group 
(F), and the HA-vaccinated group (g). (h) ADCC activities of serum samples 
that collected from each group. The percent of cytotoxicity was derived 
based on our previously described method (11). *P < 0.05 as compared to 
the PBS-treated group. The results represent mean values ± SD (n = 5).
6
Ye et al. ADCC Epitopes on HA Head
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 317
known to recognize a wide range of viral proteins that lead to the 
lysis of virus-infected cells, a better understanding on the ADCC 
mechanism during influenza virus infections will facilitate the 
development of universal influenza vaccines with broader protec-
tions (4, 9, 29). The conserved viral proteins or domains, such as 
M2 extracellular domain and HA stem domain, have been widely 
studied as potential targets of domain-based universal influenza 
vaccines. Jegerlehner and colleagues have demonstrated that the 
protective role of M2 ADCC-mediating antibodies was depend-
ent on FcR (7, 8). DiLillo et al. provided further support that the 
influenza-specific ADCC antibody, though elicited by the HA 
stem, also required FcRs interaction for protection against lethal 
influenza infection (6). Collectively, both studies highlighted 
the functional importance of FcR during ADCC-mediated virus 
clearance. On the other side, unexpected cases have been reported 
that young adults without prior exposure to the 1968 H3N2 virus 
produced robust ADCC-mediating antibody response upon 
infection of this virus strain. Some individuals even possessed 
cross-reactive ADCC-mediating antibodies toward avian H5N1 
and H7N7 strains in the absence of prior exposure (30). However, 
the mechanism of such antibody responses remains unclear to 
date.
In this study, we investigated the ADCC effect of the two puta-
tive HA head epitopes in vitro and in vivo. Our data demonstrated 
that E1-induced ADCC activity against H1N1 influenza virus 
infection in vitro (Figure 3). Unexpectedly, although E1 vaccina-
tion decreased the viral load in H1N1-infected mice (Figure 4B), 
it induced exacerbated lung damage (Figure  5) and a higher 
level of NK activity (Figure  6) that accelerated mouse death 
(Figure 4C). NK cells, which offer the first line of defense against 
virus infection, have been widely considered to be beneficial to 
the host during viral infections. However, a recent report by Zhou 
et al. revealed that adoptive transfer of NK cells from influenza 
virus-infected lungs, but not uninfected lung, resulted in a more 
rapid weight loss and increased mortality of virus-infected mice 
(31). This finding was in line with our observation that E1-induced 
ADCC exhibited deleterious impact to promote mortality during 
influenza virus infection.
Most healthy donors have a persistently low level of cross-
reactive ADCC-mediating antibodies, while these cross-reactive 
antibodies are found in individuals in the absence of detectable 
neutralization (4, 9). In our previous study, both E1 and E2 
epitopes were identified as putative regions that could induce 
ADCC activity. The depletion of such antibodies in human 
plasma significantly decreased the ADCC effect. However, for 
certain samples, it appeared that more diluted plasma exhibited 
higher ADCC activity than less diluted plasma, and the use of IgG 
antibodies at a low concentration led to a higher ADCC activity 
than the use of IgG antibodies at a high concentration (11). To 
date, there is no conclusive study on the correlation between anti-
body concentration and ADCC activity, neither was the optimal 
concentration of ADCC antibodies that could protect against 
virus infection elucidated. In this context, we demonstrated here 
that an overwhelming production of ADCC antibodies in the 
absence of neutralization might not play a protective role against 
influenza virus infection. Indeed, multiple factors such as satura-
tion of antibodies or interference from non-ADCC antibodies 
may contribute to the induction of ADCC (4, 11). In this case, the 
threshold level of protective ADCC-mediating antibodies should 
be investigated in further studies.
Various ADCC assays that mainly differ in the choice of 
effector cells and measurement of ADCC activity have been 
reported (4, 9). For example, some studies used HA-transfected 
or virus-infected A549 cells as target cells, which were susceptible 
FigUre 4 | e1-vaccinated mice are adversely affected by aDcc. (a) 
Schematic diagram of the virus challenge study. (B) Three mice from each 
group were euthanized on day 3 and 5 post-inoculation, and lungs were 
collected for detection of viral loads by RT-qPCR. Results are presented as 
bar charts with mean values ± SD. Differences between groups were 
compared using the t test. *P < 0.05 and **P < 0.01 as compared to the 
PBS-immunized group. Survival rate (c) and body weight (D) of the mice (9 
mice per group) vaccinated with PBS (red), E1 (blue), E2 (green), and HA 
(purple) were monitored for 14 days. The body weight values are shown as 
means ± SD for the mice that were alive at each time point (***P < 0.0001).
FigUre 5 | lungs of e1-vaccinated mice exhibit more severe 
histopathological changes upon influenza virus infection. Representative 
histologic sections of the lung tissues from the mice harvested on day 3 and 5 
post-inoculation were stained with H&E. The level of inflammatory infiltrate and 
thickening of the alveolar septum (as alveolar damage) was detected in 
samples from mice vaccinated with PBS (a,B), E1 (c,D), E2 (e,F), and HA 
(g,h). Lung tissues from the uninfected normal mice were included for 
comparisons (i,J). The black arrows indicate inflammatory cell infiltration. Scale 
bars represent 20 μm. (K,l) Pathological changes were scored as the criteria 
indicated in Section “Materials and Methods” (*P < 0.05; **P < 0.01).
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to NK cell-mediated ADCC after incubating with the sera from 
healthy donors or clinical blood samples (6, 32, 33). In our case, we 
isolated PBMCs from healthy mice as effector cells and measured 
the death rate of target cells in the presence of vaccinated mouse 
sera (Figure 2). At the same time, utilization of flow cytometry for 
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FigUre 6 | e1-vaccinated mice express perforin at a higher level than that of PBs-, e2-, or ha-vaccinated mice upon influenza virus infection. 
Perforin expression (red) from mouse lung tissues on day 5 post-inoculation was immunolabeled with rat anti-mouse perforin followed by goat anti-rat Alexa 594 
(a–l). Nuclei were labeled by DAPI (blue). The white arrows indicate site of perforin expressing. Scale bars represent 20 μm. (M) Quantification of the percentage of 
perforin protein expression of each group. % = (perforin positive cell/total cells) × 100 (**P < 0.01). (n) Quantitative real time RT-PCR comparing perforin mRNA 
expression levels from mouse lung tissues on day 5 post-inoculation. Data are shown as fold change compared to the perforin mRNA expression level of the PBS 
group. The results represent mean values ± SD (n = 5).
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quantitation of cell cytotoxicity provided an efficient and precise 
way to assess the ADCC responses (Figure 3). Importantly, the 
H1N1-infected LA4 cells showed a low background of cell death 
in the absence of antibodies (Figure 3C), which suggested LA4 as 
an ideal cell line for the mouse-specific ADCC assay. Collectively, 
the established in vitro ADCC assay, together with the BALC/c 
mouse model, might be applied for the evaluation of other 
influenza-specific ADCC epitopes.
Experimental mouse models are an invaluable scientific 
resource that allow comprehensive investigation of key biological 
FigUre 7 | Proinflammatory cytokines are further upregulated in the 
e1-vaccinated mice upon influenza virus infection in comparison with 
those in the PBs-vaccinated mice. Quantitative real time RT-PCR 
comparing gene expression levels of TNF-α (a), IL-1β (B), and IFN-γ (c) from 
mouse lung tissues on day 5 post-virus challenge. Data are shown as fold 
change compared to the expression level of individual gene in the PBS group 
(*P < 0.05; **P < 0.01; ***P < 0.001). The results represent mean 
values ± SD (n = 5).
questions in vivo and provide an essential platform in the study of 
many human diseases. It has been widely acknowledged that the 
mouse and human antibody repertoire share a general similarity 
(34–36). However, differences in germline antibody repertoire 
exist between species, and the number of mature naïve B  cells 
from mice is smaller than that from humans (37). Both variations 
may contribute to the dissimilarities in the antibodies elicited by 
the E1-containing fragments in humans compared to those in 
mice. Due to the diversity of the B cell antigen receptor repertoire 
between the mouse and human model, the antibodies bind to the 
same fragments in distinct host models might potentially have 
slightly different epitopes. Alternatively, there may be funda-
mental differences between murine and human in terms of the 
regulation in NK cell cytotoxic granule secretion (38).
Surprisingly, distinct expression patterns of perforin were 
detected between protein (Figure 6M) and mRNA (Figure 6N) 
levels. The discrepancy might be explained by a previous finding 
that resting murine NK cells are “pre-armed” with high amounts 
of perforin mRNA, which can be rapidly translated into protein 
upon activation in  vitro and in  vivo (38). This mechanism of 
murine NK cells facilitates a better control of perforin expres-
sion, allowing a rapid production of effector proteins without 
the need of de novo gene transcription (38). Upon activation, 
ADCC effector cells produce various cytokines such as TNF-α, 
IL-1β, and IFN-γ. Further, cytokines may represent one of the 
arming pathways that stimulate the translation of perforin (38). 
Notably, human NK cell is minimally cytotoxic at rest, expresses 
little perforin protein, and becomes potently cytotoxic only 
after cytokine activation (39, 40). Our result showed that TNF-
α, IL-1β, and IFN-γ were significantly elevated in E1-vaccinated 
group when compared with those of the PBS-treated group 
(Figure 7). In this regard, the upregulation of these cytokines 
may activate the cytotoxic perforin to cause the detrimental 
damage in mouse lungs.
In our previous study, E1 and E2 epitopes were located on 
the HA head (Figure S2 in Supplementary Material), both of 
which are conserved in H1N1 strains from 2009 (2009_H1N1) 
(11). To date, however, the role of HA head during influenza 
virus infection and ADCC activation has not been fully deline-
ated. In a recent study, DiLillo and colleagues reported that 
neutralizing antibodies targeting the HA stem but not the HA 
head were capable of conferring influenza-specific ADCC (6). 
They proposed that only the anti-stem antibodies could bind 
in a correct conformation to ligate FcRs, which was based on 
the observation that a strain-specific anti-HA head antibody 
(PY102) was unable to mediate FcγR binding and to protect 
mice. On the other hand, HA head-induced ADCC activities 
were reported by a number of other groups (41–43), which was 
in agreement with our findings. The discrepancy between these 
observations might be due to the sequential and structural 
variations among subtypes/strains of influenza virus used. 
Interestingly, although both E1 and E2 epitopes are located on 
the HA head, serum from the HA-vaccinated group did not trig-
ger a significantly elevated cytotoxicity response (Figure 3H), 
implying that additional regulators exist to control the ADCC 
activity.
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